Printer Friendly

Erytech names triple negative breast cancer as next indication for eryaspase.

M2 PHARMA-February 13, 2018-Erytech names triple negative breast cancer as next indication for eryaspase


Erytech Pharma SA (EPA: ERYP) has selected triple negative breast cancer as the next target indication to broaden the scope of eryaspase (Graspa) development in solid tumours, the company announced on Tuesday.

In 2017, the company saw positive results from a Phase 2b study of eryaspase (L-asparaginase encapsulated in red blood cells) in metastatic pancreatic cancer. The company believes it was the first-ever evidence of clinical benefit of an asparaginase-based product in a solid tumour indication.

The randomised Phase 2b study involving 141 patients investigating eryaspase in combination with chemotherapy showed a 40% reduction in risk of death rate when compared to chemotherapy alone.

These encouraging results led Erytech to conduct a comprehensive evaluation to determine other potential solid-tumour indications for developing the product.

As a result, metastatic triple negative breast cancer (TNBC) was selected as the next indication to expand the potential use of eryaspase in solid tumours. TNBC is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases.

The company has begun set-up activities of a Phase 2 proof-of-concept clinical study and it expects to enrol the first patient in Q3 2018.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 13, 2018
Previous Article:Verona Pharma updates on clinical development.
Next Article:Ondine Biomedical Inc elects Joseph Sowell, III to board.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters